Oral IgA immunotherapy
Innovation for the oral treatment of mucosal cancers
ABCELY is building the world’s first platform for orally active sIgA – based immunotherapy, revolutionizing treatment approaches for mucosal diseases.
Adressing major limitations of traditionnal IgG approaches through innovative mucosal-targeted oral sIgA technology
Targeting high-value markets in oncology and chronic mucosal diseases with significant unmet medical needs.
Scalable pipeline with rapid out-licensing opportunities creates multiple value inflection points and exit paths.
From target identification to early preclinical validation, we achieve rapid, end-to-end optimization of sIgA drug candidates in less than 8 months.
This significantly de-risks early-stage programs and accelerates time to market.
No direct competition in oral sIgA therapeutics development
First-in-Class Proprietary Assets & Out-licensing
Bio Better sIgA CDR grafting Technology
Collaborations & Strategics partnerships
Abcely has engineered a proprietary, first-in-class sIgA platform, poised to unlock unparalleled therapeutic potential by rapidly generating optimized biologic candidates.
The announcement of a cancer diagnosis is a tsunami that stops a life in its tracks, leaving indelible scars and even shattering it completely. Treatment offers repair and reconstruction, healing the body and restoring its integrity. Treatment through remission and healing gives a second chance at life, which takes on an enhanced, unprecedented and new value that every patient feels after being so afraid of losing it.
The ABCELY logo was inspired by the Japanese tradition of ceramic repair, which, instead of hiding fractures and scars, sublimates them by highlighting them in gold, creating a work of art of immense value while restoring its original functionality. Life is never the same after such an experience, both in body and soul. With humility, our logo seeks to symbolize a life rebuilt and sublimated after such a devastating illness.
